The GIST paradigm: lessons for other kinase-driven cancers.
about
Somatic DNA mutation analysis in targeted therapy of solid tumoursMelanoma: oncogenic drivers and the immune systemPersonalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisStructural and functional properties of platelet-derived growth factor and stem cell factor receptorsCrystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersThe C-kit receptor-mediated signal transduction and tumor-related diseasesTargeted therapy for cancer: the gastrointestinal stromal tumor model.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyDrug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateThe off-label use of targeted therapies in sarcomas: the OUTC'S programGastrointestinal stromal tumor - an evolving concept.Membrane-to-nucleus signaling links insulin-like growth factor-1- and stem cell factor-activated pathways.Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy.PDL1 expression is an independent prognostic factor in localized GIST.Advances in sarcoma genomics and new therapeutic targets.Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsCancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptationsMolecular markers in pediatric neuro-oncology.Genomic Grade Index predicts postoperative clinical outcome of GIST.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsSynchronous occurrence of gastrointestinal stromal tumor and acute myeloid leukemia: A case report and review of the literature.Drug repurposing for gastrointestinal stromal tumor.Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.Cancer biology and genomics: translating discoveries, transforming pathology.Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology.Whole cancer genome sequencing by next-generation methods.Role of ancillary studies in fine-needle aspiration from selected tumors.Tumor control versus adverse events with targeted anticancer therapies.Advances in the systemic treatment of cutaneous sarcomas.Advances in adjuvant therapy of gastrointestinal stromal tumors.Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.Targeting PI3K in Cancer: Any Good News?Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.Gastrointestinal stromal tumor: recent advances in pathology and genetics.Adoptive immunotherapy against sarcomas.Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib.Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity.
P2860
Q26770324-228C4853-CD41-4C44-BFC7-3E33285C4CEEQ26775598-234AAF6F-5850-4971-A2C7-07958CC4F0FDQ26800005-BB6A0B12-FEFF-4EDE-A664-4A57B63C6832Q26829546-3702F9EB-82D0-4882-9FF4-8DAA184434BAQ27667290-DC650A2D-EF6E-4C03-AD88-509D9FC55EC6Q28082793-9B5EEDC6-C2F1-4535-8E9C-D6AD9A04372CQ30419298-FF8BB680-8C62-4F52-ACEA-38EBD7601DADQ33807742-168B3691-9A87-4091-B8FF-5BB7B71CE5FCQ34074997-124B7108-C8C3-4EAE-8DC8-FF6B5E2840F9Q34289180-737733E0-14A5-4461-B0BB-FA5844C8EF23Q34441837-3C4B874B-B02A-41A7-9691-38F3BAFD77B9Q34897996-979DEE99-083B-4F1D-AAC9-DE220F56D2AFQ34928165-D98D2329-4904-4F77-95B1-A59E2A5F6071Q35014924-A0C54E8B-6686-43CC-A700-21233171E62AQ35497448-B053416D-AB5E-4022-993E-BA6424433AEEQ35798839-52586255-9FC0-473A-9F98-EE5D68C715D7Q35993346-0AFDB970-1C5F-416E-8737-F7F83905A14FQ36038823-2821F921-BDAF-4ED2-B19D-B63BB44E2CE6Q36317659-100D0E45-F5F5-4101-BCFD-41C02F854A8BQ36344704-3A200943-8147-47F4-9FBF-7FE3038C1388Q36387916-2C18A2ED-15EA-40F6-AE7E-B1E404C78B18Q36740744-AF1EE768-F4A8-48AE-8579-D26F96A63811Q36825019-661DAF94-48AE-4ADA-B596-4E1B908C1BFBQ37001194-8B87C585-F048-4655-9635-A63674A18A9AQ37058556-CDEBB673-00FA-4714-8014-42C5B76338C4Q37810056-FC930D7E-8143-462F-862E-F0A475D1F333Q37886990-BB120501-F69B-4D30-A065-6BDAEB350CFBQ37932206-C07C1C82-5DF9-4E3B-9423-D9837FFEE5A9Q37951872-BFA1ADB7-C11D-429E-8EAF-8B4395198393Q37969899-6467EBDE-31DE-47D2-9284-3200AFF25052Q38000872-C98597D0-175D-4333-817C-26C4E7097EA1Q38005627-E71A3E74-AA35-4AF0-8E70-743E4078155EQ38042638-A4D208B3-E68C-4787-9A61-6A149315CB56Q38105322-E13BE9A7-EBCA-45C1-A50B-719C21E5293DQ38195656-59207EDF-93D5-42BD-971B-D2E6C25C2E1CQ38266025-025B5594-55C2-465A-B89E-98AD2ABE1419Q38270119-31F78DA3-6D89-448A-862A-B57820868CBCQ38291193-958500F2-5A84-4D16-924B-20F9730B12FEQ38361061-BA4CB93F-9095-4537-8BE3-E883D150F693Q38673511-DCF4CCE1-D16F-48A9-B30C-F117766FC5BC
P2860
The GIST paradigm: lessons for other kinase-driven cancers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The GIST paradigm: lessons for other kinase-driven cancers.
@en
The GIST paradigm: lessons for other kinase-driven cancers.
@nl
type
label
The GIST paradigm: lessons for other kinase-driven cancers.
@en
The GIST paradigm: lessons for other kinase-driven cancers.
@nl
prefLabel
The GIST paradigm: lessons for other kinase-driven cancers.
@en
The GIST paradigm: lessons for other kinase-driven cancers.
@nl
P2860
P356
P1476
The GIST paradigm: lessons for other kinase-driven cancers.
@en
P2093
Cristina R Antonescu
P2860
P304
P356
10.1002/PATH.2798
P577
2010-10-26T00:00:00Z